LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2015.
“We have made progress with multiple drug candidates across our diverse pipeline, in each case focusing on creating an improved medicine by applying deuterium chemistry to meaningfully enhance patient care,” said Roger Tung, PhD, Chief Executive Officer of Concert Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
